[The imbalance of Th1/Th2 cytokine expression in peripheral blood mononuclear cell from asthmatic patients and the effect of erythromycin on these cytokines].
OBJECTIVE
To observe the state of Th1/Th2 cytokine expression in peripheral blood mononuclear cells (PBMCs) from asthmatic patients and the effect of erythromycin (Ery) on it.


METHODS
23 asthmatic patients and 10 healthy volunteers were included. The mRNA expression for Th1/Th2 cytokines in PBMC before and after the culture with Ery were detected by RT-PCR, considering IL-2 and IFN-gamma as Th1 cytokines, and IL-4, IL-6, IL-10 as Th2 ones.


RESULTS
The positive rate of mRNA expression for Th2-derived IL-4, IL-6, IL-10 in the study group were 18/23, 19/23 and 10/23 respectively, and those for IFN-gamma and IL-2 produced by Th1 cells were 1/23 and 13/23, respectively. In the control group, the positive rate for IL-4, IL-6, IL-10 were 0/10, 2/10 and 1/10, respectively, and those for IL-2 and IFN-gamma were both 1/10. Comparing with the control group, the positive rate of mRNA expression for IL-4 and IL-6 in PBMC from asthmatic patients were significantly higher (P = 0.00003, 0.001 respectively). After the culture with Ery for 48 h, the positive rate for IL-4 expression in the study group decreased from 18/23 to 5/23 (P = 0.0006), and IL-6 from 19/23 to 9/23 (P = 0.006). The positive rate for IFN-gamma expression was elevated while IL-2 decreased(But both had no statistical significance). There was no difference observed before and after the culture with Ery in the control group.


CONCLUSIONS
There is a predominant expression of Th2-type cytokines in PBMC from asthmatic patients. Ery can down-regulate the mRNA expression for IL-4 and IL-6 in asthmatic patients, and might convert the imbalance of Th1/Th2 cytokine expression in asthmatic patients.
Xiao
W
W
Respiratory Department, Affiliated Hospital of Shandong Medical University, Jinan 250012, China.
Yu
H
H
Zheng
C
C
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001249:Asthma / Q000097:blood* / Q000235:genetics; D016207:Cytokines / Q000235:genetics*; D004917:Erythromycin / Q000494:pharmacology*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007371:Interferon-gamma / Q000235:genetics; D016753:Interleukin-10 / Q000235:genetics; D007376:Interleukin-2 / Q000235:genetics; D015847:Interleukin-4 / Q000235:genetics; D015850:Interleukin-6 / Q000235:genetics; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D018417:Th1 Cells / Q000378:metabolism; D018418:Th2 Cells / Q000378:metabolism
D000900:Anti-Bacterial Agents; D016207:Cytokines; D007376:Interleukin-2; D015850:Interleukin-6; D012333:RNA, Messenger; D016753:Interleukin-10; D015847:Interleukin-4; D004917:Erythromycin; D007371:Interferon-gamma